drugset
drugset / Trial / NCT03417037

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037 ↗

Phase 3 Withdrawn Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

Timeline

Start
2018-05-24
Primary completion
2021-04-25
Completion
2025-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject LINRODOSTAT Small molecule 100 mg Oral
Subject Nivolumab Monoclonal antibody — —

Indications

non-small cell lung carcinoma